Sino BiologicalInc.
Sino Biological,Inc. provides recombinant protein and antibody reagents for life science researchers in China and internationally. The company offers recombinant proteins, antibodies, cDNA clones, kits, serum-free media, protein modification, qPCR primers, cell lysates, and purification reagents. It also provides comprehensive solutions, including autoimmune disease research, kinase drug discover… Read more
Sino BiologicalInc. (301047) - Total Liabilities
Latest total liabilities as of June 2025: CN¥205.26 Million CNY
Based on the latest financial reports, Sino BiologicalInc. (301047) has total liabilities worth CN¥205.26 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sino BiologicalInc. - Total Liabilities Trend (2019–2024)
This chart illustrates how Sino BiologicalInc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sino BiologicalInc. Competitors by Total Liabilities
The table below lists competitors of Sino BiologicalInc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lindian Resources Ltd
AU:LIN
|
Australia | AU$18.19 Million |
|
Helgeland Sparebank
OL:HELG
|
Norway | Nkr35.65 Billion |
|
Beijing Career International Co Ltd
SHE:300662
|
China | CN¥1.99 Billion |
|
PSG Corp. PCL
BK:PSG
|
Thailand | ฿702.46 Million |
|
Yan Tai Shuang Ta Food Co Ltd
SHE:002481
|
China | CN¥2.29 Billion |
|
Pansoft Company Limited
SHE:300996
|
China | CN¥169.81 Million |
|
Chromadex Corp
NASDAQ:CDXC
|
USA | $20.10 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Sino BiologicalInc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 30.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sino BiologicalInc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sino BiologicalInc. (2019–2024)
The table below shows the annual total liabilities of Sino BiologicalInc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥281.80 Million | +20.58% |
| 2023-12-31 | CN¥233.70 Million | +10.70% |
| 2022-12-31 | CN¥211.11 Million | +53.07% |
| 2021-12-31 | CN¥137.92 Million | -27.28% |
| 2020-12-31 | CN¥189.67 Million | +407.89% |
| 2019-12-31 | CN¥37.35 Million | -- |